

# Heliox improves minute-ventilation variability during incremental maximal exercise in COPD patients

Natalia S. Gomes, Weder A. Silva, Rafael Pena, Gaspar R. Chiappa\*

Program in Human Movement and Rehabilitation of Evangelical University of Goiás, Anápolis – GO, Brazil

## ABSTRACT

**Background:** Expiratory airflow limitation during exercise is present in a certain fraction of patients with chronic obstructive pulmonary disease (COPD) and is associated with impaired exercise performance. **Objectives:** The aim of this study was to investigate whether normoxic Heliox (79% He-21%O<sub>2</sub>) can improve minute-ventilation variability ( $\dot{V}'_E$ ) in patients with COPD. **Methods:** In a double-blind crossover study, 13 non-hypoxemic men (FEV<sub>1</sub> = 36.1 + 9.32 predicted) performed incremental cardiopulmonary tests to the tolerance limit (*Tlim*) while receiving Heliox or room air (RA). Analysis of ventilation variability was performed using *Poincaré* analyses by SD<sub>1</sub> (standard deviation 1) and SD<sub>2</sub> (standard deviation 2), for minute ventilation, tidal volume, and respiratory rate. Ventilation responses during exercise, oxygen consumption, and exercise tolerance were analyzed. Cardiac output (QT) response was monitored by impedance cardiography. **Results:** Ventilation with Heliox resulted in a decrease in oxygen uptake [ $\dot{V}O_2$ , 1161.71 ± 351.11 vs. 1238.05 ± 330.93 mL/min, P < 0.05] and carbon dioxide output [ $\dot{V}CO_2$ , 1217.41 ± 300.90 vs. 1288.02 ± 321.66 mL/min, P < 0.05] compared to room air, due to an increase in ventilation (35.37 ± 9.55 vs. 31.05 ± 7.75 L, P < 0.05) and ventilatory efficiency after Heliox inhalation (12.63 ± 2.91 vs. 9.31 ± 4.15 %, P < 0.05). The ventilation variability responses increased significantly with Heliox compared to room air. **Conclusions:** Normoxic Heliox increases minute-ventilation variability during high-intensity exercise in patients with moderate-to-severe COPD.

**Keywords:** Heliox; COPD; Dynamic hyperinflation; Ventilation; Fourier transformation

## BACKGROUND

Expiratory airflow limitation during exercise is present in a certain fraction of patients with chronic obstructive pulmonary disease (COPD) and is associated with impaired exercise performance<sup>(1-4)</sup>. The literature cites the use of nitrogen replaced by inspired helium gas, known as normoxic Heliox<sup>(5)</sup> in this population. This replacement has been reported to reduce turbulence in medium to large airways, increase the rate of expiratory flow, and reduce the work of breathing, the degree of exercise-induced dynamic hyperinflation, and the intensity of dyspnea, thereby increasing exercise tolerance<sup>(6-10)</sup>.

Studies carried out by our group<sup>(6,11)</sup> showed that the improvement in exercise tolerance is associated with an increase in the delivery of oxygen to the locomotor muscle (through improved cardiac output), as inferred by the longer delay in the deoxyhemoglobin kinetics time constant, showing a delay in peripheral extraction capacity, and increasing exercise time.

We believe that these effects can be partially explained by improvement in the minute ventilation variability ( $\dot{V}'_E$ ), associated with improvement in the metabolic capacity of skeletal muscles<sup>(6)</sup>. The lower ventilation response makes it possible to limit dynamic lung hyperinflation and reduce respiratory rate<sup>(12,13)</sup>, contributing to a decrease in respiratory burden and discomfort and improving cardiac output<sup>(14)</sup>.

Thus, the main objective of the present study was to investigate whether Heliox increases  $\dot{V}'_E$  during incremental cardiopulmonary exercise in normoxemic COPD patients. Furthermore, as the role of this

mechanism during maximal exercise has not previously been examined and as Heliox is expected to increase exercise tolerance<sup>(7,8,10)</sup>, we also sought to investigate the contribution of this mechanism to the delivery of oxygen to the leg muscles during exercise.

## METHODS

### Subjects

Thirteen non-hypoxemic (resting PaO<sub>2</sub> > 60 mmHg) males with moderate-to-severe, stable COPD (FEV<sub>1</sub>/FVC < 0.7 and post-bronchodilator FEV<sub>1</sub> < 60% pred)<sup>6</sup> volunteered to participate in the study. Subjects were free of any heart disease and musculoskeletal abnormalities. All participants signed a written informed consent form. The study protocol was approved by the Medical Ethics Committee of the Evangelical University of Goiás (51596221.4.0000.5076), Brazil.

### Study Protocol

The study was a double-blind randomized crossover investigation that involved two laboratory visits. During the first evaluation, the patients underwent a pulmonary function test and after 1h, the incremental cardiopulmonary test was performed randomly for the intervention (79% He-21% O<sub>2</sub>) or room air (RA). After 72 hours, the second cardiopulmonary test was performed. Stress tests were performed with constant pace increases up to the tolerance limit (*Tlim*, min).

\*Corresponding author: Gaspar R. Chiappa; e-mail: gaspar.chiappa@gmail.com

Submission date 28 February 2023; Acceptance date 15 April 2023; Publication date 27 April 2023

**Measurements****Pulmonary function tests**

Spirometry, lung diffusing capacity, and static lung volumes by body plethysmography were measured at baseline. Recorded values were compared with those predicted for the adult Brazilian population<sup>(15,16)</sup>. Arterial partial pressure for O<sub>2</sub> and CO<sub>2</sub> were determined in standard anaerobic conditions.

**Exercise tests**

Standard metabolic and ventilatory responses were measured breath-by-breath using a calibrated computer-based system (CardiO2 System™, Medical Graphics, St. Paul, MN), as per previous studies<sup>(6,11)</sup>.

The power increment rate during the incremental exercise test was 5-10 watts/min to provide a test duration of between 8-10 min. In each cardiopulmonary exercise test, a 12-lead electrocardiogram was used for continuous recording (Cardioperfect, Welch Allin, USA) and heart rate was automatically derived.

Carbon dioxide production (CO<sub>2</sub>), oxygen uptake consumption (V̇O<sub>2</sub>), tidal volume (V<sub>t</sub>), and respiratory rate (RR) were registered breath-by-breath. On the assumption that total lung capacity (TLC) remains constant during exercise, serial inspiratory capacity (IC) manoeuvres were performed to estimate DH (EELV= CPT - IC, L)<sup>(17)</sup>. Cardiac output (QT, L/min) and stroke volume (SV, L) were measured throughout the constant work rate test using impedance cardiography (PhysioFlow PF-05™, Manatec Biomedical, France)<sup>(18)</sup>.

**Ventilatory variability**

The breath-by-breath results of minute ventilation (V<sub>E</sub>), tidal volume (V<sub>T</sub>), and respiratory rate (fr) were exported to an Excel spreadsheet (Microsoft Corporation, USA). *Poincaré* analysis was performed to calculate  $vV'_E$  using a custom R® program (<http://www.R-project.org/>), with breath-by-breath aliquots to obtain SD<sub>1</sub> (the length of the transverse line is defined as the SD<sub>1</sub> of the plot data in a perpendicular direction) and SD<sub>2</sub> (the length of the longitudinal line is defined as the SD<sub>2</sub> of the plot data) values, normalized by the number of points in V<sub>E</sub><sup>(19-22)</sup>.

**Ventilatory efficiency**

The new index ( $\eta V'_E$ , %) was calculated from a V̇CO<sub>2</sub> - log<sub>10</sub>V<sub>E</sub> plot. The resultant plotted signal is described by the quadratic function V̇CO<sub>2</sub> = a\*V<sub>E</sub><sup>2</sup> + b\*V<sub>E</sub> + c, with the final component performing as a linear function (b \* V<sub>E</sub> + c). We termed this slope coefficient (b) as the CO<sub>2</sub> output constant-rate (CO<sub>2</sub>-CR). Thus, ventilatory efficiency could be calculated

as  $\eta V'_E = (CO_2\text{-CR}/MVV \text{ predicted} * 0.22 * 0.863) * 100$ <sup>19,23</sup>.

**Statistical Analysis**

SPSS version 26.0 statistical software was used for data analysis (SPSS, Chicago, IL, USA). In order to contrast within-subject exercise responses, paired *t* or Wilcoxon tests were used as appropriate. A one-way repeated-measures analysis of variance (ANOVA) was used to compare the physiological variables. Pearson's product moment correlation was used to assess the level of association between continuous variables. The strongest significant contributors were selected for a stepwise backward multiple regression analysis. The level of statistical significance was set at *p*<0.05 for all tests.

**RESULTS****Subject characteristics**

Patients presented age 65.21 ± 2.91 years and body mass index of 25.42 ± 4.41 kg/m<sup>2</sup> with severe forced expiratory volume in 1s (FEV<sub>1</sub>) of 36.1 ± 9.32 % of predicted (1.08 ± 0.28 L) (n = 13), forced vital capacity (FVC) of 65.7 ± 12.45 % (2.35 ± 0.43 L), and inspiratory capacity (IC) of 70.1 ± 10.0 % (2.11 ± 0.26 L). As expected, considering the inclusion criteria, all patients were non-hypoxemic at rest.

**Effects of Heliox during exercise**

Heliox breathing was associated with significant increases in metabolic and ventilatory variables (Table 1; *p*<0.01), without differences in cardiac output and stroke volume. Interestingly, only minute-ventilation variability changed during the protocol (Table 2; *p*<0.01).

The change ( $\Delta$ ) found in ventilation variability during inhalation of Heliox compared to room air was shown to have a positive correlation with increasing load (*r* = 0.603; *p* < 0.01), and  $\Delta \eta V'_E$  (0.720; *p* < 0.01).



**Table 1.** Effects of Heliox and room air on physiological and subjective responses to incremental exercise

	Room air	Heliox
Subjects, n	13	13
<i>Metabolic</i>		
$\dot{V}O_2$ (mL/min)	1238.05 ± 330.93	1161.71 ± 351.11*
$\dot{V}CO_2$ (mL/min)	1288.02 ± 321.66	1217.41 ± 300.90*
RER	0.99 ± 0.08	1.10 ± 0.09*
Power (watts)	64.62 ± 17.74	78.92 ± 20.01*
$T_{lim}$ (s)	580.01 ± 234.62	551.54 ± 238.07
<i>Ventilatory</i>		
$\dot{V}E$ (L/min)	31.05 ± 7.75	35.37 ± 9.55*
$\dot{V}E$ /power (L/watts)	0.51 ± 0.14	0.47 ± 0.22
$V_T$ (mL)	1057.81 ± 246.30	1148.23 ± 232.68*
$V_T$ /power (mL/watts)	17.77 ± 5.48	15.59 ± 6.07*
$f_R$ (breaths/min)	30.80 ± 4.61	28.90 ± 5.28*
$f_R$ /power (breaths/watts)	0.50 ± 0.14	0.41 ± 0.11*
$\eta\dot{V}E$ (%)	9.31 ± 4.15	12.63 ± 2.91*
$CO_2ACR$	2.33 ± 0.92	3.22 ± 0.94*
$\dot{V}E$ - $\dot{V}CO_2$ slope	24.24 ± 6.15	31.41 ± 8.63*
<i>Cardiovascular</i>		
Cardiac output (L/min)	11.01 ± 1.95	11.31 ± 2.70
Stroke volume (mL)	90.74 ± 13.23	94.95 ± 14.98
<i>Subjective</i>		
Dyspnea scores	7 (5.0 - 8.0)	7 (5.0 - 9.0)
Leg effort scores	8 (5.0 - 8.0)	7 (5.0 - 9.5)

**Note:** Data are presented as mean ± SD or median (range).  $\dot{V}O_2$ , oxygen uptake;  $\dot{V}CO_2$ , carbon dioxide output; RER, respiratory exchange rate;  $T_{lim}$ , tolerance limit;  $V_T$ : tidal volume;  $\dot{V}E$ : minute ventilation; MVV: maximal voluntary ventilation; \*:  $p < 0.05$  for between-intervention differences at a given time point.







**Table 2.** Effects of Heliox and room air on ventilatory variability

Variables	Room air	Heliox
<i>Ventilatory variability</i>		
SD <sub>1</sub> V'E	0.82 ± 0.21	1.01 ± 0.27*
SD <sub>2</sub> V'E	5.56 ± 3.24	6.34 ± 3.67*
SD <sub>1</sub> V'E n	15.94 ± 4.57	22.69 ± 8.88*
SD <sub>2</sub> V'E n	97.95 ± 27.52	99.61 ± 30.12
SD <sub>1</sub> /SD <sub>2</sub> V'E	17.64 ± 7.11	22.88 ± 7.11*
<i>Tidal volume variability</i>		
SD <sub>1</sub> VT	54.01 ± 21.99	54.98 ± 17.89
SD <sub>2</sub> VT	121.34 ± 64.15	126.91 ± 70.38
SD <sub>1</sub> VT n	500.68 ± 188.94	500.75 ± 180.55
SD <sub>2</sub> VT n	2194.27 ± 782.28	2014.65 ± 652.02
SD <sub>1</sub> /SD <sub>2</sub> VT	50.07 ± 18.89	50.08 ± 18.05
<i>Breathing rate variability</i>		
SD <sub>1</sub> fR	1.65 ± 0.50	1.55 ± 0.55
SD <sub>2</sub> fR	4.16 ± 1.41	4.26 ± 1.48
SD <sub>1</sub> fR n	33.77 ± 16.97	26.31 ± 7.15
SD <sub>2</sub> fR n	82.27 ± 34.81	72.76 ± 27.44
SD <sub>1</sub> /SD <sub>2</sub> fR	44.43 ± 19.84	40.71 ± 18.26

\*Note: Data expressed as mean ± SD; SD<sub>1</sub> and SD<sub>2</sub> = standard deviation of normalized ventilation (V'E), tidal volume (V<sub>T</sub>), and respiratory breathing (fR). \* p<0.05



**Figure 1.** The relationship between changes ( $\Delta$  = Heliox – room air) in SD<sub>1</sub>VE and power rate (left panel). Collectively, these data suggest that the improvement in ventilation variability with Heliox increases the rate of load achieved during cardiopulmonary testing, which determines an improvement in ventilation efficiency. SD<sub>1</sub> and SD<sub>2</sub> = standard deviation of ventilation.



**Figure 2.** The relationship between changes ( $\Delta$  = Heliox – room air) in SD<sub>2</sub>VE with  $\eta$ V'E. Collectively, these data suggest that the improvement in ventilation variability with Heliox increases the rate of load achieved during cardiopulmonary testing, which determines an improvement in ventilation efficiency. SD<sub>1</sub> and SD<sub>2</sub> = standard deviation of ventilation;  $\eta$ V'E = ventilatory efficiency.



## DISCUSSION

The literature referring to Heliox is well documented, primarily on the effect that the Heliox 79%-21%O<sub>2</sub> mixture has on reducing the work of breathing and improving exercise tolerance in patients with COPD<sup>(1,6,9,10)</sup> and that in addition to its respiratory effects, reducing the intensity of dyspnea<sup>(7,9,10,24,25)</sup>, Heliox improves oxygen supply and utilization<sup>(1,6)</sup>.

This is the first study to investigate the effects of normoxic Heliox on the determinants of ventilatory variability during heavy-intensity exercise in patients with stable COPD. The main novel findings of the present study are that Heliox: *i)* increased minute ventilation variability during exercise tolerance, and *ii)* augmented ventilation efficiency, as evidenced by the increase in CO<sub>2</sub> removal with higher minute ventilation. These effects are in line with findings in animals<sup>(26)</sup>, pediatric models of ARDS<sup>(26,27)</sup>, and adult patients with respiratory failure due to exacerbation of COPD or asthma<sup>(28)</sup>. As expected, Heliox improved CO<sub>2</sub> elimination, due to the increase in tidal volume supply, with a significant reduction in respiratory rate<sup>(29)</sup>, directly impacting the improvement in ventilation efficiency.

The gain in ventilatory efficiency is associated with better elimination of CO<sub>2</sub> per unit of ventilated air<sup>(23)</sup>, which may depend on improved ventilation through improved biomechanics of respiration. Reports in the literature demonstrate that inhalation of Heliox may allow lower peak values of respiratory pressure in patients with ARDS<sup>(30)</sup>. On the other hand, studies have shown that increased ventilation with Heliox is associated with a reduction in the pressure difference between the alveoli and the mouth, which must be developed to generate a certain flow and, consequently, a lower respiratory metabolic cost. This effect is highly desirable in individuals with COPD, where ventilation may be a constraint on physical performance<sup>(31)</sup>.

This finding is associated with characteristics specific to Heliox, as it establishes a more laminar ventilatory flow through small airways compared to oxygen<sup>(29,32,33)</sup>. These responses may be linked to the effect of Heliox on the reduction in resistance to airflow<sup>(34)</sup>, thus increasing the maximum attainable expiratory airflow rate and maximum FVL expansion, and consequently increasing maximum ventilatory capacity<sup>(6,9,10,24,34,35)</sup>. In our study, we observed this increase in ventilatory response during exercise with Heliox, despite the lack of improvement in exercise tolerance time and dyspnea scores. Increased exercise time is directly associated with a greater reduction in expiratory flow limitation<sup>(6,35)</sup>.

The effect of Heliox on  $\dot{V}'E$  was evident in our study. Studies have shown that high-intensity exercise

with Heliox generates greater increments<sup>(36,37)</sup>, because of the increase in  $V_T$ <sup>(38)</sup>. Several mechanisms may be associated with Heliox-induced hyperventilation<sup>(10,38)</sup>. Some authors have argued that the sustained low PaCO<sub>2</sub> observed in normal individuals is due, at least in part, to a drop in airway resistance under a high respiratory rate. In our study, we did not measure PaCO<sub>2</sub>, but we found a greater increase in VT with Heliox, without changes in respiratory rate. This was evidenced by the increase in the  $\dot{V}'E$  and  $\dot{V}'CO_2$  ratio. On the other hand, in our study we also found lower  $\dot{V}'CO_2$  at the peak of the exercise. However, we cannot state that there was a reduction in metabolism due to increased demand on respiratory muscles and/or an increase in peripheral muscles.

## Limitations

The present study was limited by the fact that we did not assess the dynamic hyperinflation response during exercise, and the effect of Heliox on arterial blood gas parameters and on the VD/VT ratio, although the literature has already demonstrated these effects. Another limitation of the study may be related to the non-applicability of the effect of Heliox in COPD patients with more advanced disease, who cannot tolerate higher exercise intensities, generating lower ventilatory responses.

## CONCLUSION

In conclusion, Heliox breathing may benefit COPD patients by improving ventilation variability and facilitating a better ventilatory demand response during exercise, demonstrated through improved ventilation efficiency. We are aware of some potential limitations of our study, particularly in terms of the generalizability of the results to all COPD populations. Our results, however, suggest that Heliox may be useful, particularly in normoxemic patients. Further studies are needed to determine the potential for improving ventilation variability on clinical variables in patients with COPD.

## Acknowledgements

The authors would like to thank all colleagues from the Pulmonary Function and Clinical Exercise Physiology Unit for their collaboration and our patients for their effort and enthusiastic cooperation throughout the study. All honour and glory will be given in the name of the Lord my God.

**Authors Contribution:** Conceptualization: NSG, WAS, RP and GRC. Data curation: NSG, WAS and GRC. Formal analysis: GRC. Investigation: NSG, WAS, RP and GRC. Methodology: NSG, WAS, RP and GRC. Project administration: NSG, WAS, RP and GRC.

**Financial support:** CNPq number process 422416/2018-5







## REFERENCES

1. Vogiatzis I, Habazettl H, Aliverti A, Athanasopoulos D, Louvaris Z, LoMauro A, et al. Effect of helium breathing on intercostal and quadriceps muscle blood flow during exercise in COPD patients. *Am J Physiol Regul Integr Comp Physiol* 2011; 300 (6):R1549-1559.
2. Calverley PM, Koulouris NG. Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. *Eur Respir J* 2005; 25 (1):186-199.
3. Macklem PT. Exercise in COPD: damned if you do and damned if you don't. *Thorax* 2005; 60 (11):887-888.
4. O'Donnell DE, Webb KA. The major limitation to exercise performance in COPD is dynamic hyperinflation. *J Appl Physiol* (1985) 2008; 105 (2):753-755; discussion 755-757.
5. Truebel H, Wuester S, Boehme P, Doll H, Schmiedl S, Szymanski J, et al. A proof-of-concept trial of HELIOX with different fractions of helium in a human study modeling upper airway obstruction. *Eur J Appl Physiol* 2019; 119 (5):1253-1260.
6. Chiappa GR, Queiroga F, Jr., Meda E, Ferreira LF, Diefenthaler F, Nunes M, et al. Heliox improves oxygen delivery and utilization during dynamic exercise in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2009; 179 (11):1004-1010.
7. Eves ND, Petersen SR, Haykowsky MJ, Wong EY, Jones RL. Helium-hyperoxia, exercise, and respiratory mechanics in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2006; 174 (7):763-771.
8. Laude EA, Duffy NC, Baveystock C, Dougill B, Campbell MJ, Lawson R, et al. The effect of helium and oxygen on exercise performance in chronic obstructive pulmonary disease: a randomized crossover trial. *Am J Respir Crit Care Med* 2006; 173 (8):865-870.
9. Oelberg DA, Kacmarek RM, Pappagianopoulos PP, Ginns LC, Systrom DM. Ventilatory and cardiovascular responses to inspired He-O<sub>2</sub> during exercise in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1998; 158 (6):1876-1882.
10. Palange P, Valli G, Onorati P, Antonucci R, Paoletti P, Rosato A, et al. Effect of heliox on lung dynamic hyperinflation, dyspnea, and exercise endurance capacity in COPD patients. *J Appl Physiol* (1985) 2004; 97 (5):1637-1642.
11. Queiroga F, Jr., Nunes M, Meda E, Chiappa G, Machado MC, Nery LE, et al. Exercise tolerance with helium-hyperoxia versus hyperoxia in hypoxaemic patients with COPD. *Eur Respir J* 2013; 42 (2):362-370.
12. Scorsone D, Bartolini S, Saporiti R, Braido F, Baroffio M, Pellegrino R, et al. Does a low-density gas mixture or oxygen supplementation improve exercise training in COPD? *Chest* 2010; 138 (5):1133-1139.
13. Porszasz J, Emtner M, Goto S, Somfay A, Whipp BJ, Casaburi R. Exercise training decreases ventilatory requirements and exercise-induced hyperinflation at submaximal intensities in patients with COPD. *Chest* 2005; 128 (4):2025-2034.
14. Aliverti A, Macklem PT. The major limitation to exercise performance in COPD is inadequate energy supply to the respiratory and locomotor muscles. *J Appl Physiol* (1985) 2008; 105 (2):749-751; discussion 755-747.
15. Neder JA, Andreoni S, Castelo-Filho A, Nery LE. Reference values for lung function tests. I. Static volumes. *Braz J Med Biol Res* 1999; 32 (6):703-717.
16. Neder JA, Andreoni S, Peres C, Nery LE. Reference values for lung function tests. III. Carbon monoxide diffusing capacity (transfer factor). *Braz J Med Biol Res* 1999; 32 (6):729-737.
17. O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1998; 158 (5 Pt 1):1557-1565.
18. Charloux A, Lonsdorfer-Wolf E, Richard R, Lampert E, Oswald-Mammosser M, Mettauer B, et al. A new impedance cardiograph device for the non-invasive evaluation of cardiac output at rest and during exercise: comparison with the "direct" Fick method. *Eur J Appl Physiol* 2000; 82 (4):313-320.
19. Muller PT, Utida KAM, Augusto TRL, Spreafico MVP, Mustafa RC, Xavier AW, et al. Left ventricular diastolic dysfunction and exertional ventilatory inefficiency in COPD. *Respir Med* 2018; 145:101-109.
20. Castro RRT, Lima SP, Sales ARK, Nobrega A. Minute-Ventilation Variability during Cardiopulmonary Exercise Test is Higher in Sedentary Men Than in Athletes. *Arq Bras Cardiol* 2017; 109 (3):185-190.
21. Welch R, Kolbe J, Lardenoye M, Ellyett K. Novel application of Poincare analysis to detect and quantify exercise oscillatory ventilation. *Physiol Meas* 2021; 42 (4).
22. Fernandes MVS, Muller PT, Santos MCD, da Silva WA, Guntzel Chiappa AM, Chiappa GR. Ventilatory



- variability during cardiopulmonary exercise test is higher in heart failure and chronic obstructive pulmonary disease plus heart failure than in chronic obstructive pulmonary disease patients. *J Cardiovasc Med (Hagerstown)* 2022; 23 (10):694-696.
23. Muller PT, Orro GG, Barbosa GW, Saraiva E. A new ventilatory efficiency index and accuracy for early lung diffusion impairment in non-COPD smokers. *Respir Physiol Neurobiol* 2021; 289:103670.
  24. Richardson RS, Sheldon J, Poole DC, Hopkins SR, Ries AL, Wagner PD. Evidence of skeletal muscle metabolic reserve during whole body exercise in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1999; 159 (3):881-885.
  25. Amann M, Regan MS, Kobitany M, Eldridge MW, Boutellier U, Pegelow DF, et al. Impact of pulmonary system limitations on locomotor muscle fatigue in patients with COPD. *Am J Physiol Regul Integr Comp Physiol* 2010; 299 (1):R314-324.
  26. Nawab US, Touch SM, Irwin-Sherman T, Blackson TJ, Greenspan JS, Zhu G, et al. Heliox attenuates lung inflammation and structural alterations in acute lung injury. *Pediatr Pulmonol* 2005; 40 (6):524-532.
  27. Katz A, Gentile MA, Craig DM, Quick G, Meliones JN, Cheifetz IM. Heliox improves gas exchange during high-frequency ventilation in a pediatric model of acute lung injury. *Am J Respir Crit Care Med* 2001; 164 (2):260-264.
  28. George R, Berkenbosch JW, Fraser RF, 2nd, Tobias JD. Mechanical ventilation during pregnancy using a helium-oxygen mixture in a patient with respiratory failure due to status asthmaticus. *J Perinatol* 2001; 21 (6):395-398.
  29. Beurskens CJ, Aslami H, de Beer FM, Vroom MB, Preckel B, Horn J, et al. Heliox allows for lower minute volume ventilation in an animal model of ventilator-induced lung injury. *PLoS One* 2013; 8 (10):e78159.
  30. Gentile MA. Inhaled medical gases: more to breathe than oxygen. *Respir Care* 2011; 56 (9):1341-1357; discussion 1357-1349.
  31. Pecchiari M. Effects of Heliox in Stable COPD Patients at Rest and during Exercise. *Pulm Med* 2012; 2012:593985.
  32. Hess DR, Fink JB, Venkataraman ST, Kim IK, Myers TR, Tano BD. The history and physics of heliox. *Respir Care* 2006; 51 (6):608-612.
  33. Venkataraman ST. Heliox during mechanical ventilation. *Respir Care* 2006; 51 (6):632-639.
  34. Babb TG. Breathing He-O<sub>2</sub> increases ventilation but does not decrease the work of breathing during exercise. *Am J Respir Crit Care Med* 2001; 163 (5):1128-1134.
  35. Duke JW, Zidron AM, Gladstone IM, Lovering AT. Alleviating mechanical constraints to ventilation with heliox improves exercise endurance in adult survivors of very preterm birth. *Thorax* 2019; 74 (3):302-304.
  36. Babb TG. Ventilation and respiratory mechanics during exercise in younger subjects breathing CO<sub>2</sub> or HeO<sub>2</sub>. *Respir Physiol* 1997; 109 (1):15-28.
  37. Babb TG. Ventilatory response to exercise in subjects breathing CO<sub>2</sub> or HeO<sub>2</sub>. *J Appl Physiol* (1985) 1997; 82 (3):746-754.
  38. Ward SA, Whipp BJ, Poon CS. Density-dependent airflow and ventilatory control during exercise. *Respir Physiol* 1982; 49 (3):267-277.